Our Companies' News
C-Level Executives’ Primary Data Protection Concerns Diverge By Sector – Data Security and Encryption Are Most Important in Legal, Data Backup and Recovery Are Top Priority in Education
Saama Makes State-of-the-Art Clinical Analytics Platform Available to Integrate Data from all Organizations Investigating COVID-19 Treatments
Open Invitation Issued to Corporate and Government Organizations to Mitigate Pandemic
Complia Health Secures Five-Year ContinuLink Contract Extension with Interim HealthCare Franchise Network
Complia Health and the Interim HealthCare franchise network continue a close, longstanding partnership and have extended a many-year agreement following a decade of proven success.
Seattle, WA (February 28, 2020) – Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Accolade intends to list its common stock on the Nasdaq Global Select Market under the ticker symbol ACCD.
Saama’s Growth Strategy Continues with Addition of Jonathan Burr and Gregory Simpson to Leadership Team
Campbell, CA (February 18, 2020) - Saama Technologies, Inc. (“Saama”), the number one AI clinical analytics platform company, announced today that it recently expanded its leadership team to include life science technology expert Jonathan Burr as Senior Vice President of Clinical Platform Strategy, and technology marketing leader Gregory T. Simpson as Vice President, Head of Marketing. Jonathan is responsible for growing client adoption of Saama’s existing products, and Greg is charged with building and strengthening the Saama brand. The announcement came at the start of the 11th Annual Summit for Clinical Ops Executives (SCOPE) meeting in Orlando.
Campbell, CA (February 18, 2020) - Saama Technologies, Inc., the number one AI clinical analytics platform company, announced today that it signed an agreement with Pfizer Inc. to develop and deploy an AI-powered analytics solution to reduce the challenges commonly experienced by clinical study data managers and monitors. Under this agreement, Saama’s award-winning Life Science Analytics Cloud (LSAC) platform will aggregate, transform, analyze, model and predict clinical data queries using deep learning techniques. Pfizer will provide the required ground truth clinical data and domain expertise to train Saama models to achieve the required accuracy.
Carrick Capital Partners Latest News
Saviynt Announces the Return of Converge EMEA Conference on March 11th, 2020, Featuring Keynote Speaker Dex Torricke-Barton
Mavenlink Announces Executive Advisory Board to Provide Guidance on Strategy and Go-to-market Priorities
Founding Members Keith Carlson, Ed Marshall, and Walt Weisner Bring Deep Services Industry, Consulting, and Product Expertise
Infrascale appoints high-growth, tech industry veteran Russell P. Reeder as CEO, makes several new additions to its leadership team, and secures new funding led by existing investors
What attracted you to Discovery Health Partners?
Complia Health is a leading global provider of technology and expertise for the long-term and post-acute care market. Nearly 3,000 home health, residential, community care, and hospice organizations count on Complia Health for the clinical, operational, and financial solutions required to profitability deliver quality care.
About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.